- Home
- BRTX vs PULM Comparison
BRTX vs PULM Comparison
Compare BRTX & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRTX | PULM |
|---|---|---|
| Founded | 1997 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 9.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BRTX | PULM |
|---|---|---|
| Price | $0.26 | $2.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 827.5K | 10.4K |
| Earning Date | 03-26-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $383,400.00 | $3,000.00 |
| Revenue This Year | $112.14 | N/A |
| Revenue Next Year | $139.81 | $134.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.70 | N/A |
| 52 Week Low | $0.22 | $2.15 |
| 52 Week High | $2.50 | $10.40 |
Technical Indicators
Market Signals| Indicator | BRTX | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 11.42 | 40.21 |
| Support Level | $0.22 | $2.38 |
| Resistance Level | $1.13 | $2.49 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 3.22 | 19.05 |
Price Performance
Historical ComparisonAbout BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).